Premium
Urinary 8‐hydroxydeoxy‐2′‐guanosine evaluation in a paediatric Portuguese population with Down Syndrome
Author(s) -
Primo P.,
Monteiro R.,
Vasques L.,
Figueiredo I.,
Andrade D.,
Azevedo I.,
Calhau C.
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.a1458-a
Subject(s) - oxidative stress , population , medicine , guanosine , biomarker , dementia , urinary system , antioxidant , dna damage , physiology , endocrinology , gastroenterology , biology , biochemistry , dna , environmental health , disease
In Down Syndrome (DS), oxidative DNA‐damage may play a role in the pathogenesis of mental retardation and may also contribute to the development of characteristic precocious dementia of Alzheimer type, cancer, accelerated aging and other pathologies. Urinary 8‐hydroxydeoxy‐2′‐guanosine (8‐OHdG) has been reported to serve as a sensitive biomarker of oxidative DNA damage and oxidative stress. The aim of this work was to study the oxidative DNA damage in paediatric patients with DS. For this purpose, we quantified urinary 8‐OHdG and creatinine concentration in patients with DS and in healthy control subjects. The 8‐OHdG in the 24hr urine samples was measured by HPLC‐EC. In this study we didn't found a significant difference in the excretion of 8‐OHdG between the two groups studied. However, the subgroup of children with DS that consume daily antioxidant supplements had lower excretion of 8‐OHdG then the children without supplementation. These results suggest a tendency to a higher oxidative state in the DS population and that antioxidant supplements can revert this condition. In this way, the results show the interest of further evaluations of the oxidative stress in the DS population. We also consider relevant to measure the impact of a nutritional intervention in this population. It may lower the risk of associated pathologies, improve cognitive function and delay aging in DS patients. Supported by FCT(POCTI, FEDER, Programa Comunitário de Apoio).